biopharmaceutical research

Akelos Inc. is an innovative research-based biotechnology/biopharmaceutical clinical company focused on translating innovative science into treatment. It is developing novel non-narcotic (non-opioid) drugs for the treatment of neuropathic pain, with a non-opioid drug candidate in pre-clinical development. Its development efforts focus on the HCN1 ion channel in primary sensory neurons. The company is partially funded by the National Institutes of Health (NIH) and has exclusively licensed intellectual property from Cornell University.

HCN1 ion channel targetingpatent licensingpre-clinical drug development

Apellis Pharmaceuticals is a biopharmaceutical company that develops therapies targeting C3 to treat diseases driven by excessive activation of the complement cascade, including in hematology, ophthalmology, and nephrology. Its focus areas include geographic atrophy and rare disease. Apellis has been acquired by Biogen.

clinical trialscomplement C3 targeted therapy development

Clear Scientific is a biopharmaceutical company pioneering novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body. Its lead candidate CS-1103 is a small-molecule sequestrant that binds and inactivates fentanyl, accelerating its removal from the body, and has shown positive Phase 2 results. Preclinical research also explores CS-1103 for methamphetamine overdose.

clinical trialspreclinical studies